WIN-CONSORTIUM
17.5.2019 11:40:10 CEST | Business Wire | Press release
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019.
ASCO® endorsed for the past 11 years, the WIN symposium will deliver an
exciting line-up of speakers in Paris (France) on June 23-24, 2019 to
discuss Innovation and Global Deployment of Precision Oncology.
The
current status of Precision Oncology across the globe will be examined
with the exceptional participation of the chairmen of the event, Richard
L. Schilsky, Chairman WIN Consortium(*)
, Senior
Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero,
Vice Chairman WIN Consortium, President of ESMO and Director of Vall
d’Hebron Institute of Oncology, Spain.
Global experience will be shared:
- Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA
- Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA
- The Value of Personalized Medicines for Healthcare Systems in Europe – by the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Rapidly changing landscape of Precision Medicine in Japan, Tokyo Medical and Dental University
- National Cancer Grid of India – Earthshots over Moonshots, TATA Memorial Hospital
- Development and Application of Precision Oncology in China, Fudan University Shanghai Cancer Center
World leading precision oncologists will deliver breakthrough science, including:
- Prof. Jennifer A. Doudna, PhD, University of California, Berkeley, USA “Rewriting the Code of Life: CRISPR-Cas Genome Editing”.
- Dr. Jennifer A. Ligibel, MD, Harvard Medical School and Dana Farber Cancer Institute, USA “Lifestyle-based Prevention Strategies”.
- Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “Innovation in Clinical Trials: WINTHER trial”, first study pioneered by the WIN Consortium (*) , that showed that assessing RNA is an important adjunct to DNA profiling for determining treatments and rings in a new era for personalized medicine in oncology. WINTHER results were recently published in Nature Medicine (**)
- Prof. Christophe Le Tourneau, MD., PhD, Institut Curie, France, “Innovative Ways of Assessing Durable Response under Immunotherapy”
- Dr. Jean François Martini, PhD., MSc, Pfizer Inc., “Addressing Mechanisms of Resistance Following Anti-Cancer Therapy: a Pharma Perspective”
- Prof. Angel Porgador, PhD, Ben Gurion University of Negev, Israel, “Efficient In Vitro Screening for Drug Combinations: The TEVA Model”
Do not miss the two microsatellites hosted at the WIN Symposium:
- Real-World Evidence and its Relevance for Clinical Practice and Stakeholder Decision Making - F. Hoffmann-La Roche Ltd
- Artificial Intelligence to Support Patient Profiling in Precision Oncology - Definiens AG
The WIN symposium provides outstanding networking opportunities for all professionals in cancer care.
(*) WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 11 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine, www.winconsortium.org
(**) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial https://doi.org/10.1038/s41591-019-0424-4
For more information: www.winsymposium.org
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005150/en/
Contact:
WIN Consortium Vladimir Lazar Chief Scientific and Operating Officer vladimir.lazar@winconsortium.org Telephone: + 33 66 109 15 22
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 10:00:00 CEST | Press release
Including Executives and Policymakers from the UK Government, NVIDIA, AWS, Tony Blair Institute, AstraZeneca and Virgin Atlantic The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead
MOVIVA® launch spotlight at ESGE Days 20267.5.2026 09:58:00 CEST | Press release
“Turn down the food noise” During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.”
Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 09:57:00 CEST | Press release
GBCI Europe Impact Report 2026 highlights that 53% of European real estate leaders prioritize resilience as a financial imperative. Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom